Thirdly, in addition to our accomplishments in our areas of focus, we have in parallel identified opportunities to further develop and commercialize certain of our discoveries in diagnostic and/or therapeutic areas outside of these areas, whereby our shareholders would obtain the right to share in any future success from commercializing these discoveries but without the need to commit any further Compugen financial resources.In recent months, we have announced a number of agreements including the announcement during the last quarter of the joint establishment with Merck Serono of a new biomarker company. And we expect to announce additional such arrangements in the future, thus significantly extending our strong base for future growth in shareholder value beyond our initial areas of focus.
Compugen's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.